Herbal Formula for Advanced Liver Cancer with Damp-Heat
Part of Cancer, Digestive system clinical trials.
This trial tests a Chinese herbal formula (Shuganhuazhuo) for people with advanced liver cancer who have a 'damp-heat' pattern in traditional Chinese medicine. It is given on top of your usual second- or third-line anti-cancer therapy to see if it helps control the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary liver cancer (hepatocellular carcinoma).
- Your liver cancer is at an advanced stage (called BCLC stage C, meaning it has spread).
- You have already tried at least one prior treatment and are now planning another (second or third line therapy).
- A traditional Chinese medicine doctor has identified your main pattern as 'damp-heat' (a specific syndrome).
- You are between 18 and 75 years old.
- Your doctor expects you to live longer than 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests a personalized treatment plan for people whose advanced liver cancer (hepatocellular carcinoma) has progressed after initial targeted and immune therapy. It aims to find a next-step option tailored to your specific situation.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial is testing a combination of treatments for liver cancer that cannot be removed by surgery. It combines a targeted therapy pill (lenvatinib), an immunotherapy that boosts your immune system (PD-1 blocker), a procedure that destroys tumors with heat or cold (ablation), and a chemo procedure that delivers medicine directly to the liver (TACE). The goal is to see if this mix is safe and effective.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
Hear when a new Chinese Herbal Medicine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.